Table 1.

Growth inhibitory effect of T115 in major cancer cell lines and their drug resistance subclones

Cell lineOriginGI50 (nmol/L) *
T115ColchicinePaclitaxel
MCF-7Breast4.3 ± 0.22.5 ± 0.3<0.1
MCF-7-AdrBreast (MDR+)13 ± 3327 ± 723856 ± 729
BC-19Breast (MDR+)3.2 ± 2.36.1 ± 1.533 ± 7
A2780Ovarian21 ± 83.0 ± 1.3<0.1
A2780-DXOvarian (MDR+)24 ± 612 ± 8272 ± 65
KB-3-1Cervix9.9 ± 1.52.7 ± 0.4<0.1
KB-4-D-10Cervix (MRP+)5.7 ± 2.16.5 ± 3.5<0.1
KB-V1Cervix (MDR+)21 ± 0.7757 ± 99>10000
KB-H5.0Cervix13.8 ± 3.5NDND
PC-3Prostate20 ± 76.6 ± 2.6>10000
PC-3-AdrProstate (MRP+)24 ± 1244 ± 15>10000
P388SLeukemia2.1 ± 1.00.21 ± 0.0823 ± 11
P388-VMDRCLeukemia (MDR+)2.3 ± 1.1267 ± 90238 ± 128
GM 05659Normal>10000NDND
FBCLNormal>10000NDND
  • Abbreviation: ND, not determined.

  • * Mean ± SD (n = 3).